· National Intellectual Property Administration Signs MOU on Intellectual Property with Myanmar's Ministry of Commerce · Wenzhou's Yongjia Approved to Build National Intellectual Property Rapid Protection
On June 3, China Legal Science Network released the “First Batch of High-Quality Judicial Cases Related to Artificial Intelligence.” The selection was organized by the Network
Introduction: Currently, the biopharmaceutical industry is at a critical juncture of technological paradigm transformation. Frontier tracks such as exosome drugs, nucleic acid delivery, cell therapy, and
Many clients ask when applying for a patent: “How much does it cost to apply for a patent?” Is there a way to save money? “
This issue features 10 cutting-edge research achievements covering popular areas such as placental development, heart failure, colorectal cancer, cognitive neural mechanisms, tumor immunology, lung adenocarcinoma, Parkinson’s
Biopharmaceutical financing developments for this period: Case Counsel completed a 318 million RMB Series D financing round, focusing on innovative bile acid metabolism drugs; Bate Medical
On June 15, China’s biopharmaceutical industry witnessed a historic patent ruling. Hebo Pharmaceuticals, a Chinese biotechnology company, completely defeated global pharmaceutical giant Amgen in a federal
China tops the list for the first time, with Huawei and Lantu breaking into the global top five! On May 21, the World Intellectual Property Organization
· Overseas Intellectual Property Dispute Response Guidance Council's 2026 Annual Meeting Held in Beijing · Jiangxi Issues Administrative Guidance on Intellectual Property Protection for "6·18" Online
On June 11th, the National Medical Products Administration (NMPA) approved four Class 1 innovative drugs through a priority review and approval process, covering four key areas
A Leading Chinese Intellectual Property Legal Service Provider